MRK
30
-8
IBM
57
2
DOW
32
-2
DIS
72
3
EXC
67
-2
ETR
61
-2
DTE
43
-6
AZO
55
2
PEP
45
-2
ABBV
53
-7
PSX
44
-3
FMC
31
-2
NFLX
72
2
NEE
46
-3
CL
48
-2
MU
56
-3
D
23
-2
IPG
48
3
GOOGL
51
3
VIX
30
-2
MRK
30
-8
IBM
57
2
DOW
32
-2
DIS
72
3
EXC
67
-2
ETR
61
-2
DTE
43
-6
AZO
55
2
PEP
45
-2
ABBV
53
-7
PSX
44
-3
FMC
31
-2
NFLX
72
2
NEE
46
-3
CL
48
-2
MU
56
-3
D
23
-2
IPG
48
3
GOOGL
51
3
VIX
30
-2
Financhill
Back

Capricor Therapeutics 10K Form

Sell
46

CAPR
Capricor Therapeutics

Last Price:
$13.49
Seasonality Move:
-1.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CAPR News And Ratings

See the #1 stock for the next 7 days that we like better than CAPR

CAPR Financial Statistics

Sales & Book Value

Annual Sales: $22.3M
Cash Flow: $-11.7M
Price / Cash Flow: 0
Annual Sales: $3.19
Price / Book: 4.22

Profitability

EPS (TTM): -1.20000
Net Income (TTM): $-40.5M
Gross Margin: $500K
Return on Equity: -75.99%
Return on Assets: -49.36%

Capricor Therapeutics Earnings Forecast

Key Capricor Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for CAPR have been equal to 66.76% of Gross Profit Margin.
  • The Research & Development expenses have been 224.37% of Revenue.
  • The Net Earning history of CAPR is -181.71% of Total Revenues.
  • Per Share Earnings over the last 26 years have been positive in 12 years.

Capricor Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CAPR
CUSIP: 14070B
Website: capricor.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.19
Quick Ratio: 4.17

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 28.92

CAPR Technical Analysis vs Fundamental Analysis

Sell
46
Capricor Therapeutics (CAPR) is a Sell

Is Capricor Therapeutics a Buy or a Sell?